glp-1 news Science's 2023 Breakthrough: Agonists Show Promise Against Obesity-Associated Disease GLP-1 Medications - LHD Benefit
Description
~2% in those treated with placebo) [9,10,11,12,13,14,15,16,17,18], permanent discontinuations range between 1.66% of treated patients (vs
They reduce hemoglobin A 1c (HbA 1c ), weight, major cardiovascular events, and renal decline
It should be avoided in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
These breakthroughs together are enhancing the competitive position of the market by extending the patient base, compliance, and thus GLP-1 analogue therapy continues to be in demand in both established and emerging markets
"And I'm kind of like, 'Well, it's what I'm doing now
Specific concerns: Skin reactions
